In this on-demand webinar series, Dr. Igor Makhlin discusses personalized treatment options for ER-positive, HER2-negative metastatic breast cancer, including the role of ESR1 mutation testing and ...

Vepdegestrant significantly improved progression-free survival in ESR1-mutant ER-positive, HER2-negative advanced breast cancer compared to Faslodex, with a median of 5.0 months versus 2.1 months. The ...

The FDA approved the selective estrogen receptor (ER) degrader elacestrant (Orserdu) for the treatment of postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or ...

Filing acceptance based on phase III data showing giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, versus ...

Orserdu (elacestrant) is a targeted hormonal therapy for breast cancer. Unlike chemotherapy, which can harm both healthy and cancer cells, targeted therapy aims at specific proteins in the cancer ...

For patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, the oral proteolysis-targeting chimera ER degrader, vepdegestrant, ...

A Prescription Drug User Fee Act target date of June 5, 2026 has been assigned to the application. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ...

Experts discuss the necessity of ESR1 mutation testing when considering treatment with elacestrant in patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast cancer and ...

– Filing acceptance based on Phase III data showing giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, ...